Format

Send to

Choose Destination
See comment in PubMed Commons below
Clin Infect Dis. 2008 May 1;46(9):1412-22. doi: 10.1086/528714.

Strong correlation between serum aspergillus galactomannan index and outcome of aspergillosis in patients with hematological cancer: clinical and research implications.

Author information

1
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.

Abstract

BACKGROUND:

Galactomannan is an Aspergillus-specific polysaccharide released during aspergillosis and is detected by the quantitative serum galactomannan index (GMI) test. Preclinical and preliminary clinical reports have suggested a good correlation between GMI and aspergillosis outcome.

METHODS:

We reviewed the literature to assess the strength of correlation between GMI and aspergillosis outcome using the kappa correlation coefficient. We included 27 studies that enrolled patients with hematological cancer and proven or probable aspergillosis and that used sequential GMI testing. We examined the 3 following outcomes: survival (survival vs. death), global outcome (survival vs. death [including autopsy findings]), and autopsy outcome (autopsy findings only).

RESULTS:

Overall, 257 patients fulfilled criteria for proven or probable aspergillosis and were eligible for outcome evaluation. Correlation between GMI (within <or=1 week before outcome) and defined outcomes was excellent, with kappa correlation coefficients of 0.8737 (95% confidence interval, 0.8140-0.9333; P<.001) and 0.9123 (95% confidence interval, 0.8617-0.9629; P<.001) for survival and global outcome, respectively. Most importantly, the kappa correlation coefficient for autopsy outcome was high (0.8498; 95% confidence interval, 0.5608-1.000; P<.001). Furthermore, the kappa correlation coefficient for all outcomes was comparable across age groups (pediatric and adult patients) and treatment modalities, including allogeneic transplantation. This strong correlation is also supported by extensive preclinical data and recent clinical reports.

CONCLUSIONS:

We conclude that serum GMI is a good marker of aspergillosis outcome.

PMID:
18419445
DOI:
10.1086/528714
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Silverchair Information Systems
    Loading ...
    Support Center